Neuropeptide Y (13-36), amide, human (Neuropeptide Y (13-36), human)
(Synonyms: Neuropeptide Y (13-36), human) 目录号 : GC31154
Neuropeptide Y (13-36), amide, human (Neuropeptide Y (13-36), human) 是一种选择性神经肽 Y2 受体激动剂。
Cas No.:122341-40-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.
Intraventricular injections of the Y2 neuropeptide Y receptor agonist porcine Neuropeptide Y (13-36) (25-3000 pM) produces a dose-dependent increase (up to 14%; ED50=0.3 nM for overall effects and 0.97 nM for the peak effects) in mean arterial blood pressure in the awake, unrestrains male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat[1].
[1]. Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci Lett. 1990 Oct 2;118(1):5-8.
Animal experiment: | Rats[1]Neuropeptide Y (13-36) dissolved in 30 μL mock cerebrospinal fluid (CSF), or CSF alone, is injected (30/μL/3 min) by means of an automatic micro-injection pump into the lateral ventricle of freely moving, unrestrained male rats. Five doses of Neuropeptide Y (13-36) (25, 75, 750, 1250, 3000 pM) are injected in order to evaluate possible dose-dependent effects and the effects are compared with the CSF group. A threshold dose of Neuropeptide Y (13-36) is also injected together with a dose of Neuropeptide Y (1-36) (75 pM), close to the ED50 value for its overall vasodepressor action in awake rats[1]. |
References: [1]. Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci Lett. 1990 Oct 2;118(1):5-8. | |
| Cas No. | 122341-40-6 | SDF | |
| 别名 | Neuropeptide Y (13-36), human | ||
| Canonical SMILES | Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 | ||
| 分子式 | C134H207N41O36S | 分子量 | 3000.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3333 mL | 1.6664 mL | 3.3329 mL |
| 5 mM | 0.0667 mL | 0.3333 mL | 0.6666 mL |
| 10 mM | 0.0333 mL | 0.1666 mL | 0.3333 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet